Pharma

Vertex gains FDA expansion of Casgevy to those ages 2 and older

The FDA has granted a label expansion for children ages 2 and up to receive Vertex's gene therapy Casgevy for sickle cell disease or beta thalassemia.

Kevin Dunleavy Jul 6, 2026 11:30am

Regulatory tracker: HHS to revoke remaining COVID emergency nods

Jul 6, 2026 10:45am

Designing an agentic, future‑ready tech roadmap for emerging pharma

Brought to you by ZS

Evolution step-up growth trajectory upward trajectory

How biosimilar developers are embracing next phase of US market

Jul 6, 2026 10:03am

Pharma marketers face privacy hurdles, turn to omnichannel strategies

Brought to you by Swoop

showdown clash versus vs crash lightning fight dispute

The Oral GLP-1 Tracker: $71M US sales modeled for Foundayo debut

Jul 6, 2026 9:38am